KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Working Capital Changes (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Other Working Capital Changes for 8 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 115.31% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, up 136.4% year-over-year, with the annual reading at $406973.0 for FY2025, 46.83% down from the prior year.
  • Other Working Capital Changes hit $1.7 million in Q4 2025 for Adaptive Biotechnologies, up from $395476.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $25.1 million in Q4 2023 to a low of -$56.3 million in Q4 2022.
  • Historically, Other Working Capital Changes has averaged -$3.0 million across 5 years, with a median of $135985.0 in 2021.
  • Biggest five-year swings in Other Working Capital Changes: crashed 9185.71% in 2022 and later surged 2541.85% in 2025.
  • Year by year, Other Working Capital Changes stood at -$11.4 million in 2021, then plummeted by 394.91% to -$56.3 million in 2022, then soared by 144.58% to $25.1 million in 2023, then crashed by 145.22% to -$11.4 million in 2024, then surged by 115.31% to $1.7 million in 2025.
  • Business Quant data shows Other Working Capital Changes for ADPT at $1.7 million in Q4 2025, $395476.0 in Q3 2025, and $336998.0 in Q2 2025.